BACKGROUND: Shingrix (recombinant zoster vaccine) was licensed to prevent herpes zoster, dispensed as 2 doses given 2-6 months apart among adults aged ≥50 years. Clinical trials yielded efficacy of >90% for confirmed herpes zoster, but post-market performance has not been evaluated. Efficacy of a single dose and a delayed second dose and efficacy among persons with autoimmune or immunosuppressive conditions have not been studied. We aimed to assess post-market vaccine effectiveness of Shingrix. METHODS: We conducted a cohort study among Medicare Part D community-dwelling beneficiaries aged >65 years. Herpes zoster was identified using a medical office visit diagnosis with treatment, and postherpetic neuralgia was identified using a validated algorithm. We used inverse probability of treatment weighting to improve cohort balance and marginal structural models to estimate hazard ratios. RESULTS: We found a vaccine effectiveness of 70.1% (95% confidence interval [CI], 68.6-71.5) and 56.9% (95% CI, 55.0-58.8) for 2 and 1 doses, respectively. The 2-dose vaccine effectiveness was not significantly lower for beneficiaries aged >80 years, for second doses received at ≥180 days, or for individuals with autoimmune conditions. The vaccine was also effective among individuals with immunosuppressive conditions. Two-dose vaccine effectiveness against postherpetic neuralgia was 76.0% (95% CI, 68.4-81.8). CONCLUSIONS: This large real-world observational study of the effectiveness of Shingrix demonstrates the benefit of completing the 2-dose regimen. Second doses administered beyond the recommended 6 months did not impair effectiveness. Our effectiveness estimates were lower than the clinical trials estimates, likely due to differences in outcome specificity. Published by Oxford University Press for the Infectious Diseases Society of America 2021.
BACKGROUND: Shingrix (recombinant zoster vaccine) was licensed to prevent herpes zoster, dispensed as 2 doses given 2-6 months apart among adults aged ≥50 years. Clinical trials yielded efficacy of >90% for confirmed herpes zoster, but post-market performance has not been evaluated. Efficacy of a single dose and a delayed second dose and efficacy among persons with autoimmune or immunosuppressive conditions have not been studied. We aimed to assess post-market vaccine effectiveness of Shingrix. METHODS: We conducted a cohort study among Medicare Part D community-dwelling beneficiaries aged >65 years. Herpes zoster was identified using a medical office visit diagnosis with treatment, and postherpetic neuralgia was identified using a validated algorithm. We used inverse probability of treatment weighting to improve cohort balance and marginal structural models to estimate hazard ratios. RESULTS: We found a vaccine effectiveness of 70.1% (95% confidence interval [CI], 68.6-71.5) and 56.9% (95% CI, 55.0-58.8) for 2 and 1 doses, respectively. The 2-dose vaccine effectiveness was not significantly lower for beneficiaries aged >80 years, for second doses received at ≥180 days, or for individuals with autoimmune conditions. The vaccine was also effective among individuals with immunosuppressive conditions. Two-dose vaccine effectiveness against postherpetic neuralgia was 76.0% (95% CI, 68.4-81.8). CONCLUSIONS: This large real-world observational study of the effectiveness of Shingrix demonstrates the benefit of completing the 2-dose regimen. Second doses administered beyond the recommended 6 months did not impair effectiveness. Our effectiveness estimates were lower than the clinical trials estimates, likely due to differences in outcome specificity. Published by Oxford University Press for the Infectious Diseases Society of America 2021.
Authors: Laura P Hurley; Sean T O'Leary; Kathleen Dooling; Tara C Anderson; Lori A Crane; Jessica R Cataldi; Michaela Brtnikova; Brenda L Beaty; Carol Gorman; Angela Guo; Megan C Lindley; Allison Kempe Journal: J Gen Intern Med Date: 2022-07-06 Impact factor: 6.473
Authors: Jamison Pike; Andrew J Leidner; Harrell Chesson; Charles Stoecker; Scott D Grosse Journal: Appl Health Econ Health Policy Date: 2022-02-09 Impact factor: 3.686
Authors: Yuwei Sun; Kaitlyn Jackson; Cyril A Dalmon; Brett L Shapiro; Sixiang Nie; Carmen Wong; Benjamin F Arnold; Travis C Porco; Nisha R Acharya Journal: Vaccine Date: 2021-06-08 Impact factor: 4.169
Authors: Katia J Bruxvoort; Lei Qian; Jun Wu; Ana Florea; Bradley Ackerson; Lina S Sy; Leticia Vega Daily; Harpreet Takhar; Hung Fu Tseng Journal: Open Forum Infect Dis Date: 2022-02-07 Impact factor: 3.835
Authors: Til Ramón Kiderlen; Katrin Trostdorf; Nicola Delmastro; Arne Salomon; Maike de Wit; Mark Reinwald Journal: Healthcare (Basel) Date: 2022-08-12
Authors: Brandon J Patterson; Philip O Buck; Desmond Curran; Desirée Van Oorschot; Justin Carrico; William L Herring; Yuanhui Zhang; Jeffrey J Stoddard Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2021-05-26